erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in immunohistochemical analysis

Chieh Lan, Jacqueline Ming Liu, Tsang Wu Liu, Der Hung Hsu, Shuching Liang, Jim Ray Chen, Jacqueline Whang Peng

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

We conducted this study to ascertain the prevalence of erb-b2 gene amplification in breast cancer specimens read as 2+ in immunohistochemical analysis. Slides from patients with metastatic or recurrent breast cancer were eligible for fluorescent in situ hybridization (FISH) study if they were read as 2+ immunohistochemically for erb-b2 by a certified pathologist. The PathVysion kit (Vysis, Downers Grove, IL) was used for FISH studies. Amplification of the erb-b2 gene was defined as an erb-b2/CEP17 (chromosome 17 centromere) ratio of 2 or more in 30 tumor cells counted. From May 2003 to June 2004, 221 slides were submitted from 24 hospitals around the island. Of 216 successful hybridizations, 96 (44.4%) were determined to be erb-b2 amplified. In addition, the topoisomerase IIα gene was coamplified in 11 (21%) of 53 and deleted in 8 (15%) of 53 erb-b2 amplified cases. The erb-b2 gene amplification rate was very high in cases determined to be 2+ by immunohistochemical analysis; therefore, determination of erb-b2 status by FISH in cases scored 2+ immunohistochemically is strongly recommended.

Original languageEnglish
Pages (from-to)97-102
Number of pages6
JournalAmerican Journal of Clinical Pathology
Volume124
Issue number1
DOIs
Publication statusPublished - Jul 1 2005
Externally publishedYes

Fingerprint

Fluorescence In Situ Hybridization
Gene Amplification
Breast Neoplasms
Type II DNA Topoisomerase
Chromosomes, Human, Pair 17
Centromere
Islands
Genes
Neoplasms

Keywords

  • Breast cancer
  • erb-b2
  • Fluorescence in situ hybridization
  • Immunohistochemistry
  • Topoisomerase 2α

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in immunohistochemical analysis. / Lan, Chieh; Liu, Jacqueline Ming; Liu, Tsang Wu; Hsu, Der Hung; Liang, Shuching; Chen, Jim Ray; Peng, Jacqueline Whang.

In: American Journal of Clinical Pathology, Vol. 124, No. 1, 01.07.2005, p. 97-102.

Research output: Contribution to journalArticle

Lan, Chieh ; Liu, Jacqueline Ming ; Liu, Tsang Wu ; Hsu, Der Hung ; Liang, Shuching ; Chen, Jim Ray ; Peng, Jacqueline Whang. / erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in immunohistochemical analysis. In: American Journal of Clinical Pathology. 2005 ; Vol. 124, No. 1. pp. 97-102.
@article{466558cf65e5441c9588ab6c41208424,
title = "erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in immunohistochemical analysis",
abstract = "We conducted this study to ascertain the prevalence of erb-b2 gene amplification in breast cancer specimens read as 2+ in immunohistochemical analysis. Slides from patients with metastatic or recurrent breast cancer were eligible for fluorescent in situ hybridization (FISH) study if they were read as 2+ immunohistochemically for erb-b2 by a certified pathologist. The PathVysion kit (Vysis, Downers Grove, IL) was used for FISH studies. Amplification of the erb-b2 gene was defined as an erb-b2/CEP17 (chromosome 17 centromere) ratio of 2 or more in 30 tumor cells counted. From May 2003 to June 2004, 221 slides were submitted from 24 hospitals around the island. Of 216 successful hybridizations, 96 (44.4{\%}) were determined to be erb-b2 amplified. In addition, the topoisomerase IIα gene was coamplified in 11 (21{\%}) of 53 and deleted in 8 (15{\%}) of 53 erb-b2 amplified cases. The erb-b2 gene amplification rate was very high in cases determined to be 2+ by immunohistochemical analysis; therefore, determination of erb-b2 status by FISH in cases scored 2+ immunohistochemically is strongly recommended.",
keywords = "Breast cancer, erb-b2, Fluorescence in situ hybridization, Immunohistochemistry, Topoisomerase 2α",
author = "Chieh Lan and Liu, {Jacqueline Ming} and Liu, {Tsang Wu} and Hsu, {Der Hung} and Shuching Liang and Chen, {Jim Ray} and Peng, {Jacqueline Whang}",
year = "2005",
month = "7",
day = "1",
doi = "10.1309/R2X4-KK22-QCL7-PLME",
language = "English",
volume = "124",
pages = "97--102",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "1",

}

TY - JOUR

T1 - erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in immunohistochemical analysis

AU - Lan, Chieh

AU - Liu, Jacqueline Ming

AU - Liu, Tsang Wu

AU - Hsu, Der Hung

AU - Liang, Shuching

AU - Chen, Jim Ray

AU - Peng, Jacqueline Whang

PY - 2005/7/1

Y1 - 2005/7/1

N2 - We conducted this study to ascertain the prevalence of erb-b2 gene amplification in breast cancer specimens read as 2+ in immunohistochemical analysis. Slides from patients with metastatic or recurrent breast cancer were eligible for fluorescent in situ hybridization (FISH) study if they were read as 2+ immunohistochemically for erb-b2 by a certified pathologist. The PathVysion kit (Vysis, Downers Grove, IL) was used for FISH studies. Amplification of the erb-b2 gene was defined as an erb-b2/CEP17 (chromosome 17 centromere) ratio of 2 or more in 30 tumor cells counted. From May 2003 to June 2004, 221 slides were submitted from 24 hospitals around the island. Of 216 successful hybridizations, 96 (44.4%) were determined to be erb-b2 amplified. In addition, the topoisomerase IIα gene was coamplified in 11 (21%) of 53 and deleted in 8 (15%) of 53 erb-b2 amplified cases. The erb-b2 gene amplification rate was very high in cases determined to be 2+ by immunohistochemical analysis; therefore, determination of erb-b2 status by FISH in cases scored 2+ immunohistochemically is strongly recommended.

AB - We conducted this study to ascertain the prevalence of erb-b2 gene amplification in breast cancer specimens read as 2+ in immunohistochemical analysis. Slides from patients with metastatic or recurrent breast cancer were eligible for fluorescent in situ hybridization (FISH) study if they were read as 2+ immunohistochemically for erb-b2 by a certified pathologist. The PathVysion kit (Vysis, Downers Grove, IL) was used for FISH studies. Amplification of the erb-b2 gene was defined as an erb-b2/CEP17 (chromosome 17 centromere) ratio of 2 or more in 30 tumor cells counted. From May 2003 to June 2004, 221 slides were submitted from 24 hospitals around the island. Of 216 successful hybridizations, 96 (44.4%) were determined to be erb-b2 amplified. In addition, the topoisomerase IIα gene was coamplified in 11 (21%) of 53 and deleted in 8 (15%) of 53 erb-b2 amplified cases. The erb-b2 gene amplification rate was very high in cases determined to be 2+ by immunohistochemical analysis; therefore, determination of erb-b2 status by FISH in cases scored 2+ immunohistochemically is strongly recommended.

KW - Breast cancer

KW - erb-b2

KW - Fluorescence in situ hybridization

KW - Immunohistochemistry

KW - Topoisomerase 2α

UR - http://www.scopus.com/inward/record.url?scp=21744433507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21744433507&partnerID=8YFLogxK

U2 - 10.1309/R2X4-KK22-QCL7-PLME

DO - 10.1309/R2X4-KK22-QCL7-PLME

M3 - Article

VL - 124

SP - 97

EP - 102

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 1

ER -